Clavis Pharma Completes Executive Management Team

17-Oct-2007

Clavis Pharma ASA announced the appointment of Jan Alfheim as Chief Business Officer. Mr. Alfheim has more than 20 years of international experience relating to product and corporate development within the pharmaceutical, biotech and chemical industries.

Prior to joining Clavis, Mr. Alfheim was President and Member of the Board of StemPath Inc., a position he has held since April 2005. He was Director of Business Development at Neurochem Inc from 2001-2005. Before joining Neurochem, Mr. Alfheim held senior management positions in Europe, including Director of Technology at Dyno-Radnor AS, and Project Director at Nycomed Imaging AS (now part of GE Health). Jan started his career as a research chemist in 1985 with the Center for Industrial Research (now part of SINTEF). Mr. Alfheim received a Masters of Business Administration from McGill University in 2002, and holds a Masters of Science degree in Chemistry from Concordia University. Mr. Alfheim will assume his new responsibilities at Clavis Pharma immediately and he will reside in Oslo, Norway. He succeeds Gustav Christensen who has taken up the position of Executive VP and Chief Business Officer in Dyax Inc (USA).

Following last month's announcement of the appointment of Mr. Geir Christian Melen as new CEO, and the proposed appointment of Mr. Tom Pike as Executive Chairman, this concludes the current process of strengthening and reorganising the company's management team. The combined team now encompasses substantial skills and experience from big pharma and biotech companies and all aspects of the business, including drug discovery, drug development, business development, marketing and finance.

https://www.bionity.com/en/news/72036/clavis-pharma-completes-executive-management-team.html